Deals: Page
-
Getty and BioPharma Dive
Seeking edge in oncology, Bristol-Myers bets big on blood cancer, cell therapies
Buying Celgene will marry Bristol-Myers' strong position in solid tumors with the biotech's leading blood cancer business.
By Jacob Bell • Jan. 3, 2019 -
Sarepta inks deal to bolster gene therapy manufacturing
An agreement with Aldevron may help the biotech avoid setbacks like the short-lived clinical hold it received on a gene therapy candidate last year.
By Suzanne Elvidge • Jan. 3, 2019 -
Bristol-Myers to buy Celgene in industry-shaking $74B deal
In one of the largest pharma deals ever, Bristol-Myers will acquire Celgene after a year-long share slide that raised questions about the biotech's future.
By Ned Pagliarulo , Andrew Dunn • Jan. 3, 2019 -
Courtesy of Sanofi
Sanofi ends heart drug collaboration with MyoKardia
MyoKardia executives said Sanofi's decision was not related to clinical data or safety concerns, but rather over a difference in views on expanding the deal.
By Andrew Dunn • Jan. 2, 2019 -
Merck KGaA trades rights for equity in amended CAR-T pact
New deal terms signal that German Merck has lost interest in developing Intrexon's technology in-house.
By Suzanne Elvidge • Dec. 21, 2018 -
Gilead deepens immuno-oncology push with Agenus deal
Linking up with Agenus is another step Gilead has taken to fill out its oncology ambitions. Whether the biotech succeeds will be up to Daniel O'Day, who will soon take over as CEO.
By Andrew Dunn • Dec. 20, 2018 -
DBV pulls peanut allergy treatment application, sinking shares
Regulators knocked DBV Technologies' application on a lack of detail regarding manufacturing and quality control, spurring the company to withdraw it.
By Suzanne Elvidge • Dec. 20, 2018 -
Eyeing NASH, Gilead wagers $1.5B on preclinical fibrosis drugs
With skepticism surrounding some of Gilead's more advanced NASH drugs, analysts noted its deal with Scholar Rock makes sense given the "potential for both monotherapy and combo therapies."
By Jacob Bell • Dec. 19, 2018 -
Pfizer taps Seattle-based Kineta in immunotherapy deal
The pharma, which trails other rivals in immuno-oncology, aims to uncover new ways of boosting anti-tumor immune responses through the partnership.
By Suzanne Elvidge • Dec. 18, 2018 -
Clovis dips as Tesaro reveals more details of its acquisition
Tesaro received just one takeover bid which, while at a large premium, may have unnerved Clovis investors hoping there remains a variety of PARP-focused suitors.
By Jacob Bell • Dec. 17, 2018 -
Montgomery County Planning Commission
Merck shelling out $3.7B on digital solutions for animal health
Through a new acquisition, the big pharma is going full speed into what it calls the "fastest growing part of the animal health industry."
By Jacob Bell • Dec. 14, 2018 -
Biogen backs away from AGTC after gene therapy failure
The smaller biotech lost a main revenue source and about half its market cap as one of its candidates proved safe but ineffective in a rare eye disorder.
By Jacob Bell • Dec. 13, 2018 -
Bausch bids $200M for Synergy gut drug, eyeing turnaround opportunity
Synergy thought its IBS drug Trulance would find success in a growing market. Two years since approval, the company's filed for bankruptcy and put its assets up for sale.
By Ned Pagliarulo • Dec. 12, 2018 -
Lilly bets on AC Immune's tech to target Alzheimer's
The companies' focus will be on small molecules that inhibit aggregation of a protein many believe to be integral in Alzheimer's development.
By Jacob Bell • Dec. 12, 2018 -
Masthercell doubles capacity in production build-out
With the expansion, the CDMO aims to better support its cell therapy-focused clients as they advance candidates through testing.
By Suzanne Elvidge • Dec. 6, 2018 -
Courtesy of AbbVie
AbbVie nets 7th Humira biosimilar deal, pushing Pfizer entry to 2023
The settlement allows Pfizer to launch its copy in the U.S. at the end of 2023; a European launch can go ahead as soon as approval comes through.
By Suzanne Elvidge • Dec. 5, 2018 -
J&J picks up cancer antibody from Argenx in $500M deal
Argenx shares shot up by almost 14% as Janssen gets its hands on worldwide rights to cusatuzumab for hard-to-treat blood and bone cancer.
By Suzanne Elvidge • Dec. 4, 2018 -
Dive Awards
Deal of the Year: Takeda buys Shire
The $62 billion takeout is the largest acquisition of a foreign company in Japan's history and would transform Takeda into the ninth largest pharma globally.
By Jacob Bell • Dec. 3, 2018 -
GSK buys Tesaro in $5.1B takeover deal
The British pharmaceutical giant sees PARP inhibitors as an undervalued therapeutic area and will lead efforts to expand Zejula's commercialization.
By Andrew Dunn • Dec. 3, 2018 -
Elizabeth Regan/BioPharma Dive
M&A trends in 2019: Will the biotech bubble burst?
New technologies have driven higher valuations in pharma and biotech, yet some big bankers are uncertain how long that trend will hold.
By Jacob Bell • Nov. 30, 2018 -
Sun Pharma acquires two manufacturing plants in deal for Japanese company
Acquiring Pola Pharma won't cost the Indian generics maker much, and boosts its dermatology presence in Japan.
By Suzanne Elvidge • Nov. 29, 2018 -
Roche joins NASH dash with Jecure buy
Still, Jecure's portfolio of preclinical assets leaves Roche far behind leaders in the space like Gilead and Intercept.
By Jacob Bell • Nov. 28, 2018 -
Courtesy of AbbVie
England's NHS says Humira biosimilar pacts to save more than $300M
The U.K. agency called it the biggest discount for any single drug negotiation, which closely follows the launch in Europe of four copycats of AbbVie's drug.
By Suzanne Elvidge • Nov. 27, 2018 -
Cambrex acquires Avista in $250M deal
Analysts note the deal, which gives Cambrex facilities as well as new capabilities, will make the company more competitive in the CDMO space.
By Suzanne Elvidge • Nov. 21, 2018 -
Leo, PellePharm strike rare disease deal
The agreement directs Leo Pharma into the world of rare disease therapeutics, a route increasingly taken by drugmakers.
By Suzanne Elvidge • Nov. 21, 2018
Previous
